Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Postremissions-Behandlung der akuten Leukämie im Erwachsenenalter: allogene Knochenmarktransplantation oder Chemotherapie? (1988)
    Springer
    Journal of molecular medicine 66 (1988), S. 614-623 
    Details
    ISSN: 1432-1440
    Keywords: Acute myeloid leukemia ; Acute lymphoblastic leukemia ; Postremission-therapy ; Bone marrow transplantation ; Intensified chemotherapy
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The impact of bone marrow transplantation and chemotherapy on remission duration and survival in acute leukemia is controversial. Most studies on either procedure deal with selected patients and lack randomized or concurrent controls; many exclude high-risk subgroups. There are only a few preliminary reports on the direct comparison between bone marrow transplantation and intensive chemotherapy. Considerable controversy remains as to whether patients with AML in first remission who have an HLA identical sibling should receive a bone marrow transplant at that time or whether the transplant should be delayed until relapse or second remission. In patients under the age of 25 years, results of bone marrow transplantation are considered to be equivalent or superior to those achieved with chemotherapy. Because of a high lethality rate few results suggest that survival of patients transplanted during first remission is not superior to that obtained by intensified chemotherapy; however, the relapse incidence is decreased. In recent years, results in adult ALL, treated with various intensified programs, have improved considerably and are nearly comparable to those obtained in childhood ALL. Therefore, allogeneic bone marrow transplantation is usually performed in standard risk patients during second remission and, if relapse occurs within the first three years. It is not clear at present whether ALL highrisk patients will benefit from bone marrow transplantation during first remission.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01728802
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Zum gegenwärtigen Stand der internistischen Therapie des Mammacarcinoms (1979)
    Springer
    Journal of molecular medicine 57 (1979), S. 921-926 
    Details
    ISSN: 1432-1440
    Keywords: Breast cancer ; Adjuvant chemotherapy ; Chemoimmunotherapy ; Combination chemotherapy ; Mamma-Ca ; Adjuvante Chemotherapie ; Chemoimmuntherapie ; Polychemotherapie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Für die postoperative adjuvante Chemotherapie gibt es bisher keine genau definierte Risikogruppe, bei der die Rezidiv- oder Metastasierungsrate sicher vermindert werden kann. Weitere kontrollierte Studien müssen die Indikation für diese Therapie erst noch detaillierter herausarbeiten. Von einer generellen, unkontrollierten Anwendung der adjuvanten Chemotherapie wird abgeraten. Ähnliches gilt für die unspezifische Immunstimulation, die auch keinen gesicherten positiven Effekt hat. Für die palliative Polychemotherapie, eventuell in Kombination mit einer Antiöstrogentherapie, werden 4 verschiedene Therapie-Protokolle, die sich in unseren Händen gut bewährt haben, mit ihren Indikationen vorgestellt: Adriamycin/Cyclophosphamid (AC), Cyclophosphamid/Methotrexat/5-Fluorouracil (CMF), CMF/Vincristin/Prednison (CMFVP) und die Kombination von Adriamycin/Vincristin (AV) mit CMF auf der Basis einer Dauertherapie mit Tamoxifen.
    Notes: Summary There is no well defined group of patients with primary breast cancer which benefits from combination chemotherapy as an adjuvant treatment, since, at present, the effect of this therapy in respect to the duration of disease-free interval, survival, and possible long-term side effects remain unknown. Therefore, controlled studies need to be initiated. Similarly, there seems to be no beneficial effect from unspecific immunotherapy. As far as combination chemotherapy in advanced breast cancer is concerned, we review on four different protocols which proved to be quite successful in our hands: adriamycine/cyclophosphamide (AC), cyclophosphamide/methotrexate/5-fluorouracil (CMF), CMF/vincristine/prednisone (CMFVP), and adriamycine/vincristine plus CMF plus Tamoxifen.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01478548
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...